Development of this evidence summary

This evidence summary was developed for NICE by Bazian Ltd. The integrated process statement sets out the process NICE uses to select topics for the evidence summaries for unlicensed/off-label medicines and how the summaries are developed, quality assured and approved for publication.

Project team

Bazian Ltd

Medicines and Prescribing Centre, NICE

Peer reviewers and contributors

Lizzie Amis, Senior Public Involvement Adviser, Public Involvement Programme, NICE

Expert advisers

Dr Sarah Blagden, Consultant/Senior Lecturer in Medical Oncology, Director of Phase I Cancer Trials, Imperial College London

Roche reviewed the evidence summary and provided additional technical information.

Declarations of interest

No relevant interests declared.